SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-027554
Filing Date
2023-04-05
Accepted
2023-04-05 16:15:10
Documents
14
Period of Report
2023-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea176546-8k_enzobio.htm   iXBRL 8-K 32126
2 CREDIT AGREEMENT, DATED AS OF MARCH 31, 2023, BY AND AMONG ENZO CLINICAL LABS, I ea176546ex10-1_enzobio.htm EX-10.1 566054
3 GRAPHIC ex10-1_001.jpg GRAPHIC 5160
  Complete submission text file 0001213900-23-027554.txt   907895

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enz-20230331.xsd EX-101.SCH 3212
5 XBRL LABEL FILE enz-20230331_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE enz-20230331_pre.xml EX-101.PRE 22350
8 EXTRACTED XBRL INSTANCE DOCUMENT ea176546-8k_enzobio_htm.xml XML 3584
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Filer) CIK: 0000316253 (see all company filings)

IRS No.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-09974 | Film No.: 23802711
SIC: 8071 Services-Medical Laboratories